Why Is Immuneering Stock Trading Higher On Tuesday?
On Tuesday, Immuneering Corporation (NASDAQ: IMRX ) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms .
Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows :
Also Read: Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Initial Data from Phase 2a Arm of IMM-1-104 with modified FOLFIRINOX in first-line pancreatic cancer:
Initial Data from Phase 2a of IMM-1-104 monotherapy in second-line pancreatic cancer:
Immuneering also announced initial pharmacokinetic, pharmacodynamic, and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415.
The company says further IMM-1-104 Phase 2a data are expected in the second quarter of 2025.
Immuneering says the Phase 2a arm of IMM-1-104 in combination with BRAF inhibitor in melanoma and Phase 2a arms of IMM-1-104 in combination with checkpoint inhibitors in both melanoma and NSCLC are planned for 2025.
Price Action: IMRX stock is up 61.90% at $3.82 during the premarket session at last check Tuesday.